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Abstract
Background: Sarcoidosis is a granulomatous disease characterized by a seemingly exaggerated immune response
against a difficult to discern antigen. Dendritic cells (DCs) are pivotal antigen presenting cells thought to play an
important role in the pathogenesis. Paradoxically, decreased DC immune reactivity was reported in blood samples
from pulmonary sarcoidosis patients. However, functional data on lung DCs in sarcoidosis are lacking. We
hypothesized that at the site of disease DCs are mature, immunocompetent and involved in granuloma formation.
Methods: We analyzed myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) in broncho-alveolar lavage (BAL) and
blood from newly diagnosed, untreated pulmonary sarcoidosis patients and healthy controls using 9-color
flowcytometry. DCs, isolated from BAL using flowcytometric sorting (mDCs) or cultured from monocytes (mo-DCs),
were functionally assessed in a mixed leukocyte reaction with naïve allogeneic CD4+ T cells. Using
Immunohistochemistry, location and activation status of CD11c
+DCs was assessed in mucosal airway biopsies.
Results: mDCs in BAL, but not in blood, from sarcoidosis patients were increased in number when compared with
mDCs from healthy controls. mDCs purified from BAL of sarcoidosis patients induced T cell proliferation and
differentiation and did not show diminished immune reactivity. Mo-DCs from patients induced increased TNFa
release in co-cultures with naïve allogeneic CD4
+ T cells. Finally, immunohistochemical analyses revealed increased
numbers of mature CD86
+ DCs in granuloma-containing airway mucosal biopsies from sarcoidosis patients.
Conclusion: Taken together, these finding implicate increased local DC activation in granuloma formation or
maintenance in pulmonary sarcoidosis.
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Background
Sarcoidosis is a systemic disease characterized by the pre-
sence of noncaseating granulomas in involved organs,
affecting the lung in more than 90% of patients [1,2]. The
granulomatous reaction occurs in the absence of a clearly
defined immunological target. However, a reaction to an
unidentified antigen is suspected [3]. An antigen-driven
pathogenesis is supported by disease-associated poly-
morphisms in genes encoding antigen recognizing or
antigen presenting molecules such as Toll-like receptors
and MHC class II [4]. Epidemiological and experimental
data are suggestive of airborne or infectious antigens, in
particular mycobacterial peptides, but attempts to link
sarcoidosis to a causative pathogen are difficult and
remain controversial [5-7]. Increased numbers of CD4
+
T cells in the broncho-alveolar lavage (BAL) fluid are a
further hallmark of disease [3,4]. Increased proportions
of oligoclonal CD4
+ T cells were found in the BAL from
patients with sarcoidosis, consistent with a MHC-
restricted antigen-driven process [8,9]. Both granuloma
formation and T cell alveolitis have been characterized as
Th-1 responses [3,4,10-12]. These data have led to the
hypothesis that sarcoidosis emerges from an exaggerated
Th1 immune response upon presentation of an unidenti-
fied antigen by an antigen presenting cell (APC).
Past studies on APCs involved in pulmonary sarcoido-
sis focused on alveolar macrophages [8,9,13]. However,
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(DCs) are the key APCs in the lung, responsible for pre-
sentation of antigen in draining lymph nodes, inducing
T cell activation and proliferation [14,15]. Models of
granulomatous disease in response to mycobacterial
antigens showed that DCs contribute to granuloma for-
mation [16-18]. We recently found that pulmonary
granuloma formation is dependent on the presence of
DCs and DC-induced T cell proliferation in draining
lymph nodes [19]. These data suggest that DCs are pivo-
tal mediators in the pathogenesis of sarcoidosis. Indeed,
DCs were observed in skin, lymph node and lung lesions
from sarcoidosis patients [14,20]. Lymph node granulo-
mas contained many mature DCs expressing the lyso-
some-associated membrane glycoprotein DC-LAMP,
which is induced upon DC maturation [21]. These DC-
LAMP
+ DC were typically located in the lymphocyte
layer of granulomas and adjacent to CD3
+ T cells, sug-
gesting functional DC-T cell interaction [21]. In muscu-
lar sarcoidosis, recruitment of mDCs and upregulation
of the CD40/CD40L system in affected muscles sug-
gested that mDCs would be involved in granulomatous
inflammation through antigen presentation in a Th1
immune milieu [22]. However, there is debate about the
number and function of DCs in pulmonary sarcoidosis:
numbers of myeloid DCs (mDCs) and plasmacytoid DCs
(pDCs) in peripheral blood of pulmonary sarcoidosis
patients were reported to be either normal or reduced
[21,23]. On the other hand, proportions of pDC and
mDC in the BAL of sarcoidosis patients were reported to
be similar and increased, respectively, when compared
with healthy controls [24]. Also, decreased proportions of
BAL mDCs were found positive for CD83 and CD86,
suggesting an immature phenotype of these cells [24,25].
Furthermore, peripheral blood mDCs and in vitro differ-
entiated monocyte-derived DCs (mo-DCs) from sarcoi-
dosis patients demonstrated either a decreased or a
normal ability to stimulate T cells in co-culture experi-
ments [23,26]. These data have led to the prevailing opi-
nion that in pulmonary sarcoidosis, DCs are immature
and anergic in the lung [25]. Thus, the exaggerated
immune response in pulmonary sarcoidosis is paradoxi-
cally associated with DCs displaying diminished immu-
noreactivity. Studies into this area have been hampered
by technical difficulties in isolating functionally active
DCs with a high degree of purity from the site of active
disease. It therefore remained unclear whether pulmon-
ary DCs are functionally different in sarcoidosis.
In this study, we set out to investigate whether local
DCs are functionally different in patients with pulmonary
sarcoidosis, employing our recently developed cell sorting
strategy to isolate functionally active DCs from BAL fluid
[27]. We found that at the site of disease, more and
mature DCs are present in association with granulomas.
Furthermore, DCs from patients with sarcoidosis display
intrinsic properties associated with induction of an exag-
gerated immune response.
Materials and methods
Patients and healthy control subjects
After informed consent, a total of 44 patients with sarcoi-
dosis underwent fibre-optic bronchoscopy. The diagnosis
of sarcoidosis was made according to the guidelines of
the ATS/ERS/WASOG statement on sarcoidosis [2].
None of the patients were on systemic corticosteroid or
immunosuppressive drugs one year previous to or at the
time of diagnosis and sampling. Patient characteristics
are shown in Table 1. 34 healthy controls (male/female
ratio of 11/22, median age 22.5 (19-31), 3 smokers)
underwent fibre-optic bronchoscopy with BAL (14 con-
trols) or mucosal biopsies (20 controls, from a previous
study). As a further control, BAL from three subjects, all
smokers, who underwent bronchoscopy to exclude pul-
monary sarcoidosis (a 41 yr old patient with uveitis, a 32
yr old patient with ocular vasculitis and a 50 year old
patient with parotic enlargement), and that were found
to be without sarcoidosis or signs of pulmonary disease
at time of bronchoscopy or during 2 years of follow up,
was used. The protocol was approved by the Medical
Ethical Committee of the Erasmus MC in Rotterdam. In
different experiments, samples from subsets of patients
and controls were used due to limits in sample availabil-
ity. When applicable, key characteristics of patient/con-
trol subsets are mentioned with each experiment.
Collection of BAL, peripheral blood cells and mucosal
biopsies
BAL was performed with a flexible fibre-optic broncho-
scope (Olympus) placed in the right middle lobe in
wedge position. Four aliquots of 50 ml saline were
instilled and subsequently gently aspirated. BAL fluid was
collected in siliconized bottles to prevent cell adherence
and kept at 4°C. BAL fluid was filtered through a 100 μm
cell strainer (BD Biosciences) and centrifuged for 7 min
at 450 g at 4°C. Supernatants were aliquoted for ELISA.
A portion of BAL fluid cells were counted and used
directly to assess DC number and phenotype. Remaining
BAL cells were frozen in 1 ml RPMI 1640 (Gibco), 10%
FCS, 10% DMSO in a cryovial using a 5100 Cryo 1°C
Freezing Container (Nalgene) to -80°C and stored at
-150°C. Upon thawing, macrophages were depleted
before further flowcytometric analysis or sorting, as
described previously [27]. Peripheral blood mononuclear
cells (PBMCs) were collected as described before and
used directly to assess DC number and phenotype or fro-
zen as described above [27]. Mucosal biopsies were fro-
zen in Tissue Tek, O.C.T. compound, (Sakura Finetek
Europe) and stored at -80°C.
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PBMCs, BAL cells or cultured DCs were incubated in
FACS buffer (PBS supplemented with 0.25% BSA, 0.5 mM
EDTA and 0.05% NaN3 and stained with the following
antibodies: FITC-conjugated anti-CD3 (UCHT1), anti-
CD14 (61D3), anti-CD56 (MEM188), anti-CD4 PE-Cy5
(RPA-T4), anti-CD123-PE (6H6), anti-FoxP3-APC, all
from eBiosciences, FITC-conjugated anti-CD16 (3 G8),
anti-CD19 (HIB19) and anti-CD25 (2A3), PE-conjugated
or biotinylated anti-CD80 (L307.4), anti-CD86 (2331(FUN-
1)) or CD45RO (UCHI-1), APC-conjugated anti-CD83
(HB15e) and anti-CD40 (5 C3), anti-CD11c PE-Cy5 (B-ly6)
and anti-HLA-DR PE-Cy7 (L243), all from BD Biosciences,
as well as anti-CD123-APC (AC145, Miltenyi), anti-
CXCR3-PE (49801)(R&D) and anti-DC-LAMP-PE (104.
G4) (Immunotech). 1% heat inactivated human serum was
added to prevent non-specific antibody staining. Fixable
Aqua Dead Cell Stain kit for 405 nm (Invitrogen, Molecu-
l a rP r o b e s )w a su s e da sal i v e /dead marker. Cells were mea-
sured on a LSRII Flowcytometer (BD Biosciences). pDCs
and mDCs were recognized based on forward and side
scatter characteristics and expression of different markers.
A FITC-labeled lineage mix, containing antibodies against
CD3, CD14, CD16, CD19 and CD56 was used. mDCs were
alive, low autofluorescent, lineage mix negative, HLA-DR
+
cells, CD11c
+ cell, pDCs were CD11c
- but CD123
+. Isola-
tion of mDCs from thawed BAL cells was performed using
a FACS ARIA (BD Biosciences with Diva software and for
analysis FlowJo software (Tree Star Inc.) was used. In a pre-
vious study, we showed that mDCs do not show an altered
phenotype or altered T cell activating capacity after a
freeze-thaw cycle [27].
Immunohistochemistry of airway mucosa biopsies
Immunohistochemistry was performed in a half automatic
stainer (Sequenza) using primary monoclonal antibodies
against human CD11c (SHCL-3; BD Biosciences) and
CD86 (2331(FUN-1); BD Biosciences). DCs were identified
based on morphology and CD11c positivity in a haema-
toxylin background staining, as previously described [28].
Control staining was performed with an irrelevant mAb of
the same subclass. All biopsy sections were stained in one
session to reduce inter-staining variation and analysed in a
blinded fashion by two different researchers. Sections from
lung mucosal biopsies fulfilled the following criteria: intact
epithelium, a subepithelial mucosa of 100 μm depth and a
good overall morphological quality.
Functional testing of DCs in vitro
Isolated BAL mDCs were mixed with allogeneic naïve
CD4
+ T cells isolated from a healthy donor as described
previously [27] in a 1:20 ratio and cultured in RPMI 1640
medium at 37°C for 5 days. At day 5, a portion of the cells
was harvested for flow cytometry measurements and to
the remaining cells 3H-thymidine (0.5 μCi/well, Packard)
was added and after 16 hours cell proliferation was deter-
mined by scintillation counting (Top count model B9912/
VI, Packard Bioscience Benelux). In order to culture mo-
DCs, monocytes were isolated from PBMCs using CD14
beads (Miltenyi), according to the manufacturer’s instruc-
tions. Monocytes were then resuspended at 1 × 10
6 cells/
ml in RPMI 1640 culture medium, supplemented with
10% FCS, 50 μg/ml gentamycin (Gibco), 1000 U/ml GM-
CSF (Immuno Tools) and 200 U/ml IL-4 (R&D) and cul-
tured at 37°C for 7 days [27]. Mo-DCs were co-cultured
with allogeneic naïve CD4
+ T cells for 5 days. T cell label-
ing with carboxyfluorescein succinimidyl ester (CFSE)-was
performed using standard procedures.
Cytokine measurements in supernatants of DC-T cell
co-cultures was performed using the human in a 25-plex
Luminex assay cytokine and chemokine kit (Invitrogen,
Carlsbad, CA) and run on a Luminex 100 System (Lumi-
nex Corporation, Austin, TX), according to the manufac-
turer’sp r o t o c o l .
Table 1 Patient characteristics
Patients (n = 44)
Age, years 37.5 (18-67)
Sex, male/female 17/27
Smoking, yes/no 8/36
Stage, (I/II) 21/23
Diagnosis based on:
Biopsy 17
CD4/8 ratio 27
CD4/8 ratio, mean 4.8 (1.2-10)
Extra-thoracic sarcoidosis (number of subjects) Eye (12), Skin (10), Joints/Arthralgia (9)
Co-morbidities
(number of subjects)
Cardiovascular, including hypertension (3),
Diabetes Mellitus (2), Thyroid disease (2)
Sickle-cell disease (1), Psoriasis (1), Migraine (2)
Data are presented as median (range), unless otherwise stated.
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Results were compared using a two-tailed Mann Whit-
ney U test. Differences were considered significant at
P ≤ 0.05.
Results
BAL characteristics
In this study we investigated BAL, peripheral blood and
mucosal biopsies from newly diagnosed sarcoidosis
patients and healthy controls (see: Mat & Methods and
Table 1 for patient characteristics). Sarcoidosis patients
displayed increased BAL cellularity (median: 327 × 10
3
total cells/ml), compared to healthy controls (median:
118 × 10
3 total cells/ml, p = 0.06), in agreement with pre-
vious reports [27,29,30]. This increased cellularity in BAL
was paralleled by increased proportions of lymphocytes
and increased CD4/CD8 ratios (median: 4.8; range 1.2-
22). BAL lymphocytes in sarcoidosis are reported to be
highly positive for the Th1-specific chemokine receptor
CXCR3 [31]. Accordingly, the closely related CXCR3
ligands CXCL9, also known as monokine induced by
IFNg- (MIG) and CXCL10, also known as IFNg-induced
protein of 10 kDa (IP-10), are elevated in BAL fluid [32].
When we measured the levels of these chemokines in
BAL fluid in the same patients tested for mDC function,
we found that they were elevated: for CXCL9 the median
was 533 pg/ml (range 65-1397) in patients and 43 pg/ml
(range 21-59; p = 0.0004) in healthy controls and for
CXCL10 these values were 360 pg/ml (range 34-957) in
patients and 0 pg/ml (0-96; p < 0.003) in controls.
Increased mDCs in BAL and blood in sarcoidosis
To investigate DCs in pulmonary sarcoidosis, we first
analyzed the numbers of DC subsets in BAL and periph-
eral blood from patients (mDC (n = 16), pDC (n = 8))
and healthy controls (n = 6). The gating strategy used to
identify mDCs and pDCs, shown in Figure 1, was pre-
viously published by us and others [27,33]. The propor-
tions of HLA-DR
+CD11c
+ mDCs in total BAL cells did
not significantly differ between sarcoidosis patients and
healthy controls (median: 0. 2 6 % ,r a n g e :0 . 0 7 - 1 . 4a n d
median: 0.17%, range: 0.03-0.43, respectively; Figure 2A),
corroborating earlier studies [24]. However, the absolute
numbers of mDCs were significantly elevated in patients
(median 608 cells/ml, range: 217-3,965), when compared
with healthy controls (median 123 cells/ml, range: 101-
1,941, p = 0.05).
In the BAL from sarcoidosis patients the populations
of interleukin-3 receptor (IL-3R)/CD123-expressing
HLA-DR
+CD11c
- pDCs were increased, both in propor-
tions (median 0.06%, range 0.02-0.36, compared with
healthy controls: median 0.03%, range 0.01-0.08, p =
0.03) and in absolute numbers (median: 201 cells/ml,
range: 23-1740, compared with healthy controls: median
17 cells/ml, range 11-133, p = 0.02; Figure 2A).
In order to further validate these results, we addition-
ally analyzed proportions of mDCs and pDCs in macro-
phage-depleted BAL from 15 patients and 9 controls.
Median age of patients in this subgroup was 37 years
(range: 23-69, 1 smoking) and controls 29 years (range:
21-50, 4 smoking). Controls consisted of 6 healthy con-
trols and 3 individuals without pulmonary disease in
whom there were a need to exclude sarcoidosis (see also
Mat & Methods). After macrophage depletion, propor-
tions of mDCs and pDCs were generally higher, as was to
be expected. The proportions of mDCs in macrophage-
depleted BAL were significantly elevated in patients
(median 1.61%, range: 0.55-3.2), when compared with
healthy controls (median 1.01%, range: 0.26-1.60, p =
0.025; Figure 2B). Proportions of pDCs in macrophage-
depleted BAL tended to be higher in patients (median
0.16%, range: 0.03-0.88), when compared with healthy
controls (median 0.11%, range: 0.03-0.52), but were not
significantly different (Figure 2B).
In a blood sample, concurrently drawn from the
patients who’sB A Lf i n d i n g sa r er e p o r t e di nF i g u r e2 A ,
we observed an increase in mDCs in sarcoidosis patients,
both in proportions (median: 0.24%, range: 0.03-1.71,
compared with healthy controls 0.11%, range 0.08-0.13,
p = 0.01) and in numbers (median: 1,441/ml, range: 511-
14,432, compared with healthy controls: median 933,
range 638-1,102, p < 0.01; Figure 2C). In contrast, no dif-
ferences were observed in pDC numbers or proportions
between patients and controls (Figure 2C). Peripheral
blood from sarcoidosis patients and healthy controls also
did not differ in the total numbers of PBMCs per ml
(data not shown). Overall, we did not observe an associa-
tion between numbers of mDCs or pDCs in BAL or
blood and disease stage, as classified by Scadding [34]
(data not shown).
Next, we set out to investigate whether the increase in
DCs in BAL of sarcoidosis patients was associated with
enhanced maturation of DCs in BAL and blood. In per-
ipheral blood the expression of the CD80, CD86, CD40,
CD83 and CD208 maturation markers on mDCs or
pDCs was low and did not differ between sarcoidosis
patients and healthy control subjects (data not shown).
When analyzing CD40, CD80 (B7-1), CD83, CD86 (B7-
2), and CD208/DC-LAMP expression on mDCs and
PDs from BAL we found considerable heterogeneity in
marker expression in repeat experiments, precluding
conclusions on differences in BAL mDC maturation
between sarcoidosis patients and controls
In summary, in recently diagnosed sarcoidosis patients
we found an increase in mDCs and pDCs in the BAL and
mDCs in peripheral blood, irrespective of disease stage.
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immunocompetent
Next, we evaluated whether an increase in mDCs in the
BAL from sarcoidosis patients was associated with either
enhanced or diminished T cell activation, the latter of
which has been suggested for blood-derived DCs in sar-
coidosis [25]. We applied our previously developed flow
cytometric strategy for the isolation of mDCs from BAL
to sort mDCs from BAL of 9 sarcoidosis patients (1
smoker, median age 29, range 23-64) and 6 healthy con-
trols (no smokers, median age 22.5, range 20-24). In a
previous study we showed that using a newly developed
technique mDCs can be isolated from BAL using flow
cytometric sorting with a high degree of purity (approxi-
mately 94%, range 91,6-96,6) [27]. To test the capacity
of these sorted mDCs to induce T cell proliferation and
differentiation, we performed co-culture experiments
with allogenic naïve CD4
+ T cells. Upon 5 days of co-
culture, naïve CD4
+ T cells displayed clear proliferation,
when compared with unstimulated CD4
+ Tc e l l s .N o
differences were found between co-cultures with BAL
mDCs sorted from healthy controls or from sarcoidosis
patients (as measured by 3H-thymidine incorporation;
Figure 3A). In these co-culture experiments naïve CD4
+
T cells differentiated into CD25
+CD127
lowFoxp3
+ regu-
latory T cells, CD45RO
+ memory T cells, CXCR3
+ Th1
or CCR4
+ Th2 cells, whereby we did not observe signifi-
cant differences between co-cultures with mDCs from
sarcoidosis patients and with mDCs from healthy con-
trols (Figure 3B). Likewise, we found similar levels of
cytokines, including TNFa,I F N g,I L - 4 ,I L - 5 ,I L - 1 3a n d
IL-17 (Figure 3C).
Taken together, these findings indicate that mDCs
from the BAL from sarcoidosis patients were functional
and did not display diminished immunoreactivity, when
compared with mDCs from healthy controls.
Monocyte-derived DCs from sarcoidosis patients induce
increased TNFa expression
To investigate whether intrinsic DC defects in sarcoidosis
might lead to aberrant T cell responses independent of the
lung microenvironment, we cultured monocyte-derived
DCs (mo-DCs) from 10 sarcoidosis patients and 10
healthy controls. Expression of CD80, CD86, CD40 and
CD83 was comparable in the two groups (Figure 4A).
When mo-DC function was tested in co-cultures with
allogeneic naïve CD4
+ T cells, mo-DCs from sarcoidosis
patients and healthy controls did not manifest differences
in their capacity to induce T cell proliferation (Figure 4B),
T cell activation as assessed by membrane expression of
the IL-2R/CD25 (Figure 4C), or regulatory T cell differen-
tiation (Figure 4D). When cytokine production was mea-
sured by Luminex bead assays, we observed increased
TNFa expression in co-cultures of mo-DCs from sarcoi-
dosis patients, when compared with co-cultures of mo-DC
from healthy controls (Figure 4E). Other cytokines tested,
including IFNg, IL-17, IL-4, IL-5 and IL-13 were not dif-
ferent between the two groups of cultures.
Taken together, these data show that DCs from sar-
coidosis patients examined outside of the disease micro-
environment were not intrinsically more mature, but do
show an increased propensity to induce the production
of TNFa, a cytokine pivotal in sarcoidosis pathogenesis.
Increased numbers of mature CD86
+ DCs surrounding
granulomas
Finally, we determined the numbers, location and activa-
tion status of DCs in the airways in mucosal airway biop-
sies from 26 sarcoidosis patients and 20 healthy controls.
Identification of DCs in biopsy material can be hampered
by the absence of one marker unique for DCs; CD11c can
be expressed on monocytes, macrophages and neutrophils
as well. However, in combination with morphological
Figure 1 Gating and sorting strategy for mDCs and pDCs. Dead cells were excluded from the total fraction of the BAL cells using DAPI
as a dead-live marker (not shown). The alive, low auto fluorescent, lineage mix (CD3-, CD14-, CD16-, CD19-, CD56-) FITC negative fraction
was expressed in the Pe-Cy7 channel for HLA-DR expression. HLA-DR positive cells were subsequently expressed in the PE-Cy5 channel for
CD11c expression. Cells positive for CD11c are mDCs. CD11c negative cells were expressed in APC for CD123: cells positive for CD123 are
pDCs.
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histological sections, as we ha v ep r e v i o u s l ys h o w n[ 2 8 ] .
Cells positive for CD11c showing a characteristic DC mor-
phology were found in the subepithelial layer of the air-
ways in healthy subjects, as reported previously [35]
(Figure 5A). Ten out of 26 mucosal biopsies from sarcoi-
dosis patients contained clear granulomas, and in those
CD11c
+ DCs were seen predominantly surrounding the
granulomas, confirming earlier studies [21] (Figure 5B).
We also observed weak CD11c expression in the center of
granulomas, perhaps reflecting CD11c expression on mye-
loid derived epithelioid histiocytes or interdigitating den-
drites. Granuloma-containing biopsies displayed
significantly increased CD11c
+ cell numbers, when com-
pared with either healthy controls (p = 0.0011) or non-
granulomatous biopsies (p = 0.0014) (Figure 5C).
Figure 2 Increased mDCs in BAL and blood in sarcoidosis. Proportions and numbers of mDCs and pDCs in BAL, Macrophage (M-)depleted
BAL and peripheral blood from sarcoidosis patients and healthy controls. Using 9-color flowcytometry, the proportion of mDCs (low
autofluorescent, lineage mix negative, HLA-DR
+, CD11c
+ cells) and pDCs (low autofluorescent, lineage mix negative, HLA-DR
+, CD11c
-, CD123
+
cells) was determined of total BAL cells (A), Macrophage (M-)depleted BAL cells (B), and PBMCs from peripheral blood (C). The number of mDCs
and pDCs was calculated as a proportion of total counted BAL cells and PBMCs. Each symbol represents an individual patient or control; lines
indicate medians. * p < 0.05; ** p < 0.01.
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double stainings were performed for CD11c and CD86.
In granuloma-containing biopsies, the proportions of
CD11c
+ cells co-expressing CD86 was significantly
increased (median 88%, range 77-96%), when compared
with healthy controls (median 50%, range 4-95) (p =
0.0012), but not significantly different from values in
non-granulomatous biopsies from patients (median 82%,
range 0-100%). The proportion of CD86
+ DCs tended to
be higher in non-granulomatous biopsies, compared
with healthy controls, but differences did not reach sig-
nificance, probably related to the variation of CD86
+
expression in healthy individuals.
Taken together, these results show that granuloma
formation was associated with an increase in number
and maturation status of DCs, providing evidence for
the involvement of DCs in granuloma formation or
maintenance in sarcoidosis.
Figure 3 BAL mDCs from sarcoidosis patients are immunocompetent in co-cultures with T cells. Induction of T cell proliferation and
differentiation by mDCs isolated from BAL from sarcoidosis patients. mDCs (defined as low autofluorescent, lineage mix negative, HLA-DR
+,
CD11c
+ cells), isolated from BAL from sarcoidosis patients and healthy controls, were tested in a MLR with naïve allogeneic CD4
+ T cells. (A)
After 5 days of co-culture, T cell proliferation was measured using 3H-thymidine incorporation. (B) T cell differentiation was assessed using
markers for Tregs (CD25+ Foxp3
+ CD127
low, memory T cells (CD45RO
+), Th1 (CXCR3
+) and Th2 (CCR4
+) cells. (C) Cytokines were measured in
the supernatant of the co-culture using a bead-based cytokine kit. Data are presented as boxplots, whiskers indicate minimum and maximum of
the data.
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DCs are pivotal antigen presenting cells and the prime
suspects for initiating granuloma formation and T cell
alveolitis characteristic for pulmonary sarcoidosis. Para-
doxically, local DCs have been suggested to be phenoty-
pically and functionally immature [25]. In contrast, we
provide in this report the involvement of mature, func-
tional DCs in pulmonary sarcoidosis. First, pulmonary
sarcoidosis patients have increased numbers of mDCs in
BAL, granuloma containing mucosal biopsies and blood.
Second, mDCs in granuloma-containing biopsies show
increased expression of a maturation marker. Third,
Figure 4 Monocyte-derived DCs from sarcoidosis patients induce increased TNFa expression. Activation and function of mo-DCs from
sarcoidosis patients and healthy controls. (A) After culturing mo-DCs from monocytes, mean expression of DC maturation markers CD40, CD80,
CD83 and CD86 was assessed by flowcytometry. (B) Mo-DC induced T cell proliferation was tested in a MLR after 5 days of co-culture with CFSE-
labeled naïve CD4
+ T cells, using flowcytometry. (C, D) Mo-DC induced T-cell differentiation was measured by expression of CD25 (C) and Treg
markers (CD25
+Foxp3
+CD127
low)(D). (E) Cytokine production in DC-T cell co-cultures. Indicated cytokines were measured in the culture
supernatants by Luminex. Data are presented as boxplots, whiskers indicate minimum and maximum of the data; * p ≤ 0.05.
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T cell proliferation and differentiation and show no
signs of anergy. Finally, mo-DCs from sarcoidosis
patients induce more TNFa in co-cultures with allo-
geneic CD4
+ T cells, compared to mo-DCs from healthy
controls. Taken together these results indicate that pul-
monary sarcoidosis is associated with increased numbers
of mature, functionally competent DCs that intrinsically
induce increased levels of a central mediator in sarcoi-
dosis, TNFa.
Previous studies and ours report different results in
numbers of mDCs in blood or BAL from sarcoidosis
patients [21,23,24]. These differences may reflect varia-
tions in obtaining (e.g. volume of total BAL fluid), iso-
lating (enriched cell populations vs. flow cytometric
sorting), calculating (number per ml vs. proportions)
and markers used for defining DC subsets. E.g we found
increased proportions and numbers of mDCs in blood
from sarcoidosis patients compared to healthy controls
by calculating mDCs as the proportion of PBMCs from
the same sample, while others reported (similar) num-
bers of mDCs as a proportion of total leucocytes,
obtained by lysis of red blood cells, and calculated from
a concurrent drawn blood sample [23], or even decreased
numbers of mDCs calculated by using proportions of a
DC-enriched cell population [21]. We performed BAL
with 200 ml saline, compared to e.g. 100 ml in other
reports [24]. It is conceivable that an increase in BAL
fluid amount reduces the relative contribution of the lar-
ger conducting airways to the retrieved amount of fluid,
thus increasing the cellular yield from the alveolar com-
partment, increasing the yield of DCs.
To the best of our knowledge we report for the first
time functional tests on mDCs from the site of disease
in pulmonary sarcoidosis. DCs isolated from BAL from
sarcoidosis patients did not induce enhanced T cell
Figure 5 Increased numbers of mature CD86
+ DCs surrounding granulomas in sarcoidosis. Location, number and activation of DCs in
mucosal airway biopsies. (A) CD11c staining on a frozen section from a mucosal airway biopsy from a healthy control, showing DCs in the
subepithelial layer. Characteristic dendritic cell morphology was observed with dendrites crossing the basement membrane (insert). (B) In
mucosal biopsies from sarcoidosis patients DCs were observed surrounding the granuloma. (C) Quantification of the numbers of CD11c
+ cells in
lamina propria in biopsies from healthy controls (HC), sarcoidosis patients without (SRC) and with granuloma (SRC gr), bars indicate median
values, ** p < 0.0015. (D) Proportions of CD11c
+ cells co-expressing CD86 in biopsies from healthy controls (HC), sarcoidosis patients without
(SRC) and with granuloma (SRC gr). Each symbol represents and individual patient or control. Lines indicate median value, ** p < 0.0015 (D).
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cant differences in the induction of several cytokines in
a MLR with allogeneic naïve CD4+ T cells, compared to
controls. Several explanations related to the micro-
environment of the lung where DC-T cell interactions
take place, are possible: First, DCs from BAL from sar-
coidosis patients may have already interacted with
T cells, and are beyond their functional maximum upon
isolation from BAL. This is supported by studies show-
ing that after initial exposure to a stimulus, DCs pro-
duce IL-12, important for inducing T cell proliferation,
for a limited period of 10-18 hours [36]. Second, it is
perhaps the sheer number of DCs and not the matura-
tion status that determines the in vivo outcome of T cell
proliferation in sarcoidosis. Although the number of
DCs in BAL is in general very low, DCs in the BAL are
thought to reflect only a small percentage of pulmonary
DCs [37]. We found increased numbers of mDCs per
ml of BAL in sarcoidosis patients, perhaps indicating
increased numbers of interstitial DCs that may travel to
the draining lymph node for antigen presentation.
Future investigations in the lymph node compartment
may shed light on this issue. Third, perhaps an intrinsic
T cell factor is (additionally) required to induce the
exaggerated T cell response observed in sarcoidosis.
Interestingly, a single nucleotide polymorphism (SNP) in
the IL-23 receptor was recently associated with sarcoi-
dosis [38]. IL-23 is a cytokine that is essential for the
induction of IL-17 producing CD4
+ T cells (Th17 cells)
that were recently associated with granuloma formation
in sarcoidosis by us and others [38,39]. Interestingly, we
did observe a modest but not significant increase in IL-
17 production in the MLR supernatant of sarcoidosis
patients. Finally, influx of CD4
+ T cells into the bronch-
oalveolar space may primarily be determined by chemo-
tactic factors. Our data on enhanced levels of MIG and
IP10 in BAL, well-known chemotactic factors for Th1
cells, support this notion and confirm earlier reports
[32,40].
TNFa is a pivotal mediator of granuloma formation
and maintenance, and is thought to play an important
role in sarcoidosis pathogenesis [41]. Indeed, enhanced
TNFa secretion by BAL macro-phages is observed in sar-
coidosis [3]. In addition, TNFa is also expressed by Th1
and Th17 cells and both T helper cell subsets are likely
involved in sarcoidosis pathogenesis [38]. Polymorphisms
in the TNFa locus were associated with sarcoidosis phe-
notype and prognosis and have been linked to altered
TNFa expression [42,43]. Importantly, TNFa is an essen-
tial target for treatment [44] and we found that mo-DCs
from patients with sarcoidosis, not influenced by the
micro-environment of the lung, induced increased TNFa
release upon interaction with naïve CD4
+ T cells when
compared to controls. Our results indicate that DCs are
intrinsically different in sarcoidosis patients. Neverthe-
l e s s ,w ef o u n dt h a tm o - D C sf r o ms a r c o i d o s i sp a t i e n t s
were equally capable of inducing proliferation and differ-
entiation in allogeneic naïve T cells, compared to healthy
controls. In the current study we did not explore whether
mo-DCs from sarcoidosis patients lead to skewing of T
cell differentiation towards a Th1/Th17 phenotype com-
pared to controls, and this remains to be investigated. In
c o - c u l t u r e sw i t hP B M C s ,m o - D C sw e r ep r e v i o u s l y
reported to demonstrate a reduced capacity to induce T
cell proliferation (26). However, it is conceivable that
other cells in the PBMC fraction, e.g. regulatory T cells
(Tregs), influenced T cell proliferation. Indeed, we found
increase numbers of Tregs in the PBMC fraction from
sarcoidosis patients’ blood (unpublished observations).
Granulomas are thought to arise upon failure of the
immune system to clear invading pathogens. Earlier
reports on diminished DC maturation and immune
reactivity led to the notion that DC anergy may contri-
bute to granuloma formation in sarcoidosis, e.g. due to
diminished antigen presenting capabilities or ineffective
induction of a T helper cell response [25]. However, we
f o u n dt h a tb o t hm D C si nB A La n di ng r a n u l o m a - c o n -
taining airway biopsies were increased in number and
had enhanced expression of maturation marker CD86 in
the vicinity of granulomas. Furthermore, mDCs isolated
from BAL displayed normal immune reactivity com-
pared to healthy controls. Intriguingly, also in non-gran-
ulomatous mucosal airway biopsies from sarcoidosis
patients there was a tendency towards increased num-
bers and maturation of mDCs, compared to healthy
controls, although this was not statistically significant. It
is tempting to speculate that these mucosal DCs are
activated upon acquiring antigen from the airway lumen
a n ds u b s e q u e n t l yp r e s e n tt h ea n t i g e ni nad r a i n i n g
lymph node or are involved in mucosal granuloma for-
mation. Taken together our results strongly support the
notion that mDCs are involved in granuloma formation
and maintenance in sarcoidosis, rather than the alterna-
tive that DCs are defective in supporting the adaptive
immune system in antigen clearance. Our study
included patients with newly diagnosed stage I/II sarcoi-
dosis, we did not include patients with stage III/IV dis-
ease, and our results are therefore limited to patients
presenting with early disease. We did not find a correla-
tion between stage I or II and number of mDCs or
pDCs. However, chest X-ray stage often poorly corre-
lates with disease activity or progression. Thus, the role
of DCs in granuloma formation or maintenance in sub-
jects with advanced disease remains to be determined.
In conclusion, we provide evidence for the involvement
of DCs in antigen presentation and granuloma formation
at the site of disease in pulmonary sarcoidosis patients.
Intrinsic genetic alterations in key APCs may underlie
Berge et al. Respiratory Research 2012, 13:33
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Page 10 of 12the exaggerated immune response to a hard to discern
antigen that is characteristic of sarcoidosis. Immunologi-
cal measurements and functional examination of DC and
T cell subsets from large groups of carefully genotyped
patients should prove very interesting.
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